research use only
Cat.No.S4149
|
In vitro |
DMSO
: 59 mg/mL
(199.81 mM)
Water : 59 mg/mL Ethanol : 4 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 295.27 | Formula | C15H12NO3.H2O.Na |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 61618-27-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)[O-].O.[Na+] | ||
| Targets/IC50/Ki |
COX-2
150 nM
COX-1
250 nM
|
|---|---|
| In vitro |
Amfenac is a potent inhibitor of both COX-1 and COX-2 with IC50 of 0.25 and 0.15 μM.
|
| In vivo |
Amfenac possesses both antipyretic and analgesic properties in vivo. Amfenac (4 mg/kg) suppressed acute (Evans blue-carrageenan pleural effusion) and chronic (adjuvant-induced arthritis) inflammation by 33% and 28%, respectively, which is 16.4 and 22.8 times more potent than phenylbutazone. The analgesic activity of Amfenac is 43 times that of acetylsalicylic acid in the Randall-Selitto assay, and 156 and 56.3 times more potent than phenylbutazone in the acetylcholine-induced abdominal constriction in mice and in the bradykinin-induced nociceptive response in dogs, respectively. Amfenac produces less gastric irritation than acetylsalicylic acid when applied topically to the exposed gastric mucosa of cats or when administered orally to rats and dogs. Upon subchronic oral administration to rats, the therapeutic ratio of Amfenac is twice that of phenylbutazone.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.